

Insights into Life & Health reinsurance

Earnings growth drivers for the coming years

Claude Chèvre, Member of the Executive Board 23rd International Investors' Day 2020 Hannover, 21 October 2020



Agenda


- 1 Strategy and past performance
- 2 Earnings growth drivers
- **3** Expected COVID impact
- 4 Key take-aways

Strategy and past performance

hannover re

1

1



Support our clients in optimising consumer experience and risk segmentation




Provide our clients with tailored risk-transfer solutions beyond our core expertise




Identify and actively manage value-destroying risks in our portfolio

Life & Health: NPE (net premium earned)




NPE special effects In EUR m. 442 199 44 2015 2016 2017 2018 2019



NPE split per reporting category








- Switch from single to annual premium payment for large longevity block (2015)
- Large single premium longevity block closed for new business (2015 2016)
- Impact of new C-ROSS solvency regime in China (2015 - 2017)

 Normalised NPE growth (2015 - 2019): EUR +882 m.

Life & Health: EBIT







- Strong EBIT growth over period 2015 -2019
- EBIT volatility due to one-off effects

- Recapture of two FinSol treaties (2015)
- Recaptures after premium increases for former ING Re portfolio (2017 - 2018)
- Revaluation of Viridium investment (2019)
- Absolute amount of one-off effects (positive & negative): EUR 413 m.
- Normalised EBIT growth (2015 2019): EUR +149 m.

Life & Health: Strategy

Support our clients in optimising consumer experience and risk segmentation

- Deepen data analytics expertise in combination with artificial intelligence
- Widen data analytics service offering, including third-party data
- Expand partnerships: consumer experience & digitalisation of sales channels
- Enhance lifestyle & wellness product propositions



Outperform the competition in the fastest growing L&H markets

• Expand our offering in Asia, Longevity and Financial Solutions



Provide our clients with tailored risk-transfer solutions beyond our core expertise

• Select appropriate partners to address investment, biometric & expense risk

Identify and actively manage value-destroying risks in our portfolio

- Expand inforce management capabilities and activities
- Derive appropriate pricing from lessons learned for new business



mewhat liµerent

Earnings growth drivers



Earnings growth drivers Financial Solutions






- Providing Financial Solutions to our clients has been one of our most successful growth areas
- Bottom line growth has been very strong with the US as a significant contributor
- Premium has been flat. However, this is not a relevant indicator since many deals do not show any IFRS premium
- For the future, we still see a lot of opportunities in the US and also expect to further grow in other markets

hannover re

• Expected additional EBIT by 2023: EUR 120 m.




Normalised EBIT in EUR m.

Earnings growth drivers Longevity






- Hannover Re has been very successful in longevity markets over many years
- In the last years, we have seen strong bottom line growth with slight consolidation on the premium side
- We expect strong growth both in new regions and in new solutions
- Expected additional EBIT by 2023: EUR 80 m.



EBIT in EUR m.


Earnings growth drivers Asia






- Hannover Re has seen strong top and bottom line growth in Asia
- We expect above-average growth potential for Asia

• Expected additional EBIT by 2023: EUR 50 m.



EBIT in EUR m.

Earnings growth drivers Illustrated



Life & Health earnings growth drivers

- Our most relevant earnings growth drivers for the coming years will be Financial Solutions, Asia and Longevity
- These drivers are interrelated and there is naturally some degree of overlap


Traditional business

- A large part of our book still consists of traditional business outside of the main growth drivers
- We expect stable results here

Life & Health: Consolidated expected EBIT

Before Covid-19 impact

In EUR m.



Consolidated normalised EBIT Expectation by 2023: EUR 600 m.

somewhat dijjerent


Expected COVID impact

2

hannover re®

Expected COVID-19 impact in 2020/21





somewhat di_{ff}erent



Key take-aways

4

hannover **re**®

Key take-aways

Since 2015

Strong annual normalised EBIT growth of 10%



EBIT expected to grow to EUR 600 m.



Key earnings growth drivers

- Financial Solutions
- Longevity
- Asia



Covid-19 expected to impact 2020/21 results, 2023 targets might be delayed by one year

Disclaimer

This presentation does not address the investment objectives or financial situation of any particular person or legal entity. Investors should seek independent professional advice and perform their own analysis regarding the appropriateness of investing in any of our securities.

While Hannover Re has endeavoured to include in this presentation information it believes to be reliable, complete and up-todate, the company does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such information.

Some of the statements in this presentation may be forward-looking statements or statements of future expectations based on currently available information. Such statements naturally are subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements.

This presentation serves information purposes only and does not constitute or form part of an offer or solicitation to acquire, subscribe to or dispose of, any of the securities of Hannover Re.

© Hannover Rück SE. All rights reserved. Hannover Re is the registered service mark of Hannover Rück SE.